^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Thyroid Gland Carcinoma
    Drug:Koselugo (selumetinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

    Excerpt:
    ......
    Trial ID:
    NCT00970359
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer

    Excerpt:
    ...Complete Remission Rate (Expressed as Percentage of Patients in Complete Remission) at 18 Months Post-RAI Treatment; Subgroup Analysis BRAF/NRAS Mutation Positive`Clinical Remission Rate (Expressed as Percentage of Patients in Clinical Remission) at 18 Months Post-RAI Treatment; ITT Analysis Set`Clinical Remission Rate (Expressed as Percentage of Patients in Clinical Remission) at 18 Months Post-RAI Treatment; Subgroup Analysis BRAF/NRAS Mutation Positive...
    Trial ID:
    ASTRA
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    PLoS One
    Title:

    AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines

    Excerpt:
    AZD1480 inhibited the growth of all RET-mutated/rearranged cell lines after 1 (MZ-CRC1, TT) and 2 days (TPC-1) of treatment (p<0.0001; Fig. 1A) and minimally decreased the growth of C643,...We observed that AZD6244 minimally decreased the growth of C643 and MZ-CRC1 after 4/5 days of treatment (p<0.001; Fig. 1A and S1)...and decreased TPC-1 growth by 50% after 5 days of treatment. In contrast, AZD6244 efficiently inhibited the growth of BRAF- mutant K1 cell line (Fig. S1).
    DOI:
    https://doi.org/10.1371/journal.pone.0046869